Genome-wide association identifies novel etiological insights associated with Parkinson’s Disease in African and African admixed populations
Objective: To provide a genome-wide association study (GWAS)- based insight into the genetics of Parkinson’s disease (PD) in Africans and African admixed populations. Background: Understanding…Transferrin as a possible CSF biomarker in neurodegenerative proteinopathies
Objective: The aim of this study was to determine whether cerebrospinal fluid (CSF) levels of transferrin differ between patients with Parkinson´s disease (PD), multiple system…Exosomal α-synuclein in Multiple system atrophy and parkinson’s disease cause distinct synucleinopathies
Objective: In this study, we investigated the differences in exosomal α-syn between MSA and PD patients. Background: Parkinson's disease (PD) and multiple system atrophy (MSA)…An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials
Objective: To present results in the subset of patients with multiple system atrophy (MSA) and relevant MSA subgroups from two ampreloxetine phase 3 trials for…Peripheral Synucleinopathy in Essential Tremor Plus Patients with Parkinsonian Features and Normal Dopamine Transporter Imaging
Objective: To describe results of skin biopsy for phosphorylated alpha-synuclein (P-SYN) in patients with essential tremor (ET) with parkinsonism. Background: Patients with longstanding ET may…Microglial activation facilitates alpha synuclein propagation and neurodegeneration in αSyn preformed fibrils (PFF)-injected PD mouse model
Objective: To evaluate whether microglial activation aggravates synucleinopathy progression in Parkinson's disease (PD) mouse model. Background: Alpha-synuclein (αSyn) accumulation underlay the main pathological process of…Central olfactory structure atrophy is linked to synucleinopathy conversion in idiopathic REM sleep behavior disorder
Objective: We hypothesized that early structural changes in the brain olfactory relevant structures may help early identification of those at risk of future disease conversion…Addressing pathological alpha-synuclein aggregation using a small molecule strategy
Objective: The discovery of cell-permeable, orally bioavailable and brain penetrant small molecules with the potential of inhibiting aggregation and intracellular accumulation of pathological alpha-synuclein (a-syn)…Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies
Objective: Prothena is developing active vaccine candidates targeting α-synuclein (α-syn) epitopes shown in clinical and/or preclinical studies to disrupt synuclein pathology. These vaccines, which target…The anti-alpha-synuclein antibody Lu AF82422 was safe and well tolerated in a FIH-SAD study in healthy subjects and patients with PD
Objective: Evaluation of safety, tolerability, pharmacokinetics (PK) and target engagement (TE) in healthy subjects (HS) and patients with Parkinson’s disease (PD) following single ascending doses…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 15
- Next Page »